J. Kyula

发表

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

G. Nuovo, M. Coffey, K. Twigger, 2012, BMC Cancer.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

V. Roulstone, J. Kyula, E. Karapanagiotou, 2012, Expert opinion on biological therapy.

Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.

P. Johnston, D. Longley, J. Kyula, 2008, Cancer research.

An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.

V. Khoo, A. Thompson, J. Kyula, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.

V. Roulstone, J. Kyula, K. Harrington, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients

G. Nuovo, M. Coffey, V. Roulstone, 2012, Science Translational Medicine.

Adair Tumor in Patients Cell Carriage , Delivery , and Selective Replication of an Oncolytic Virus in

G. Nuovo, M. Coffey, V. Roulstone, 2012 .

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma

V. Roulstone, J. Kyula, R. Vile, 2022, Journal for ImmunoTherapy of Cancer.

Combination therapy with oncolytic viruses and immune checkpoint inhibitors

V. Roulstone, J. Kyula, A. Melcher, 2020, Expert opinion on biological therapy.

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cells

V. Roulstone, J. Kyula, R. Vile, 2022, bioRxiv.

Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.

V. Roulstone, J. Kyula, E. Karapanagiotou, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

P. Johnston, D. Longley, J. Kyula, 2010, Clinical Cancer Research.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status

J. Kyula, K. Harrington, H. Hafsi, 2018, Front. Oncol..

Tumor cells independently of Their p53 status

J. Kyula, H. Hafsi, U. Schick, 2018 .

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade

J. Kyula, A. Melcher, K. Harrington, 2022, Journal for ImmunoTherapy of Cancer.

Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.

P. Johnston, D. Longley, J. Kyula, 2011, Cancer research.

Therapeutics , Targets , and Chemical Biology Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM 17

P. Johnston, D. Longley, J. Kyula, 2011 .

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

V. Roulstone, J. Kyula, K. Harrington, 2019, Journal of Immunotherapy for Cancer.

Targeted radiosensitization by the Chk1 inhibitor SAR-020106.

J. Kyula, K. Harrington, M. Verheij, 2013, International journal of radiation oncology, biology, physics.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

M. Coffey, V. Roulstone, J. Kyula, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling

Roulstone, V. Roulstone, J. Kyula, 2014, Oncogene.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

J. Kyula, S. Bhide, K. Harrington, 2017, BMC Cancer.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy

G. Nuovo, M. Coffey, K. Twigger, 2012, Gene Therapy.

Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling

M. Coffey, V. Roulstone, J. Kyula, 2016, Oncotarget.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer

V. Roulstone, J. Kyula, A. Melcher, 2016, Gene Therapy.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues

Hardev S. Pandha, Kevin J. Harrington, Simon P. Robinson, 2018, Science Translational Medicine.

Synergistic antitumour effects of rapamycin and oncolytic reovirus

V. Roulstone, J. Kyula, A. Melcher, 2018, Cancer Gene Therapy.

Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells

P. Johnston, D. Longley, J. Kyula, 2006, Molecular Cancer Therapeutics.

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

V. Roulstone, J. Kyula, A. Melcher, 2013, Oral oncology.

Synergistic antitumour effects of rapamycin and oncolytic reovirus

V. Roulstone, J. Kyula, A. Melcher, 2018, Cancer Gene Therapy.

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism

V. Roulstone, J. Kyula, A. Melcher, 2020, Molecular therapy oncolytics.

Radiation lays down covering fire for viral shock troops

J. Kyula, K. Harrington, A. Khan, 2013, Oncotarget.

Adenovirally Delivered Enzyme Prodrug Therapy with Herpes Simplex Virus–Thymidine Kinase in Composite Tissue Free Flaps Shows Therapeutic Efficacy in Rat Models of Glioma

J. Kyula, A. Melcher, R. Vile, 2015, Plastic and reconstructive surgery.

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

V. Roulstone, J. Kyula, M. Dillon, 2023, bioRxiv.

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling

V. Roulstone, J. Kyula, V. Jennings, 2024, bioRxiv.